data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Coherus BioSciences
(NASDAQ:CHRS)
7.50
0.11[1.49%]
At close: Jun 24
7.50
00
After Hours: 4:04PM EDT
15 minutes delayed
Day High/Low7.22 - 7.66
52 Week High/Low5.6 - 19.32
Open / Close7.48 / 7.5
Float / Outstanding61.1M / 77.4M
Vol / Avg.1.8M / 1M
Mkt Cap580.7M
P/E-
50d Avg. Price8.2
Div / Yield-
Payout Ratio-
EPS-1.24
Total Float61.1M

Coherus BioSciences (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences (NASDAQ: CHRS)

Day High/Low7.22 - 7.66
52 Week High/Low5.6 - 19.32
Open / Close7.48 / 7.5
Float / Outstanding61.1M / 77.4M
Vol / Avg.1.8M / 1M
Mkt Cap580.7M
P/E-
50d Avg. Price8.2
Div / Yield-
Payout Ratio-
EPS-1.24
Total Float61.1M
Benzinga - Jun 14, 2022, 5:08AM
Benzinga - May 20, 2022, 9:25AM
Benzinga - May 9, 2022, 7:18AM
Benzinga - May 5, 2022, 5:16PM
Benzinga - May 5, 2022, 4:45PM
Benzinga - May 2, 2022, 9:48AM
Benzinga - May 2, 2022, 9:22AM
Benzinga - May 2, 2022, 7:20AM
Benzinga - Apr 14, 2022, 8:34AM
Benzinga - Mar 29, 2022, 9:17AM
Benzinga - Mar 15, 2022, 12:06PM
Benzinga - Mar 15, 2022, 7:36AM
Benzinga - Mar 15, 2022, 7:36AM
Benzinga - Mar 7, 2022, 5:03AM
load more
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.480-1.000 -0.5200
REV68.950M60.115M-8.835M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Coherus BioSciences Questions & Answers

Q
How do I buy Coherus BioSciences (CHRS) stock?
A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Coherus BioSciences's (CHRS) competitors?
Q
What is the target price for Coherus BioSciences (CHRS) stock?
A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by UBS on Tuesday, June 14, 2022. The analyst firm set a price target for 7.00 expecting CHRS to fall to within 12 months (a possible -6.67% downside). 6 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Coherus BioSciences (CHRS)?
A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $7.5 last updated Today at June 24, 2022, 8:00 PM UTC.

Q
Does Coherus BioSciences (CHRS) pay a dividend?
A

There are no upcoming dividends for Coherus BioSciences.

Q
When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?
A

Coherus BioSciences’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Coherus BioSciences (CHRS) going to split?
A

There is no upcoming split for Coherus BioSciences.

Q
What sector and industry does Coherus BioSciences (CHRS) operate in?
A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.